Multiple Myeloma Q&A: CAR-T, Bispecifics, IVIG, Bone Health, Genetics and Relapse

Drs. Jorge Monge, Tara Gregory, Peter Forsberg, Jeff Matous, and Nurse Kate Mimken field audience questions on the topics patients ask about most: how long IVIG (immunoglobulin) support should continue after treatment ends, how to prevent and manage peripheral neuropathy from Velcade, what predicts CAR-T neurotoxicity (ICANS) and how bridging therapy reduces that risk, where bone-strengthening drugs like Zometa and Reclast fit into treatment today, why bispecific antibodies, CAR-T, and antibody-drug conjugates sometimes stop working (including antigen escape and data from the PRISM trial), whether whole-genome sequencing could eventually replace FISH testing, how they choose treatment strategies for high-risk myeloma, when palliative care should become part of a patient's team, how clinical trials are selected for individual patients, and whether a myeloma vaccine is realistic in the future.